ArticleOncoimmunology2021
PD-L2 based immune signature confers poor prognosis in HNSCC.
Article in Oncoimmunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer.Frontiers in immunology · 2022Pooled it
- Review
- Immunomodulatory properties of human dental pulp stromal cells: the role of IL-6/JAK/STAT3 pathway and PD-L1.Frontiers in immunology · 2026Article
- PD-L2 Landscape and Correlation with Outcome: An Immunomic Analysis.JCO oncology advances · 2026Article
- Next-generation immunotherapies for head and neck squamous cell carcinoma: targeting novel immune checkpoints.Annals of medicine · 2025Review
- PD-1, PD-L1, and PD-L2 Expression as Predictive Markers in Rare Feline Mammary Tumors.Veterinary sciences · 2025Article
- Differences in PD-L1, PD-L2, and EGFR Expression Between Naive and Recurrent Tumors in Patients With Head and Neck Squamous Cell Carcinoma: A Retrospective Study.Head & neck · 2025Article
- Article
- Exploring correlations between gut mycobiome and lymphocytes in melanoma patients undergoing anti-PD-1 therapy.Cancer immunology, immunotherapy : CII · 2025Article
- Differential Immune Checkpoint Protein Expression in HNSCC: The Role of HGF/MET Signaling.International journal of molecular sciences · 2024Article
- Glycosylation in the tumor immune response: the bitter side of sweetness.Acta biochimica et biophysica Sinica · 2024Review
- Identification of lncRNA dual targeting PD-L1 and PD-L2 as a novel prognostic predictor for gastric cancer.Frontiers in oncology · 2024Article
- Linking tumor immune infiltrate and systemic immune mediators to treatment response and prognosis in advanced cervical cancer.Scientific reports · 2023Article
- Personalised Medicine and the Potential Role of Electrospinning for Targeted Immunotherapeutics in Head and Neck Cancer.Nanomaterials (Basel, Switzerland) · 2023Review
- Inhibitory checkpoint molecule mRNA expression in canine soft tissue sarcoma.Veterinary and comparative oncology · 2023Article
- Immune Checkpoint Inhibitors, Small-Molecule Immunotherapies and the Emerging Role of Neutrophil Extracellular Traps in Therapeutic Strategies for Head and Neck Cancer.International journal of molecular sciences · 2023Review
- The Concordant Disruption of B7/CD28 Immune Regulators Predicts the Prognosis of Oral Carcinomas.International journal of molecular sciences · 2023Article
- Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy.British journal of cancer · 2023Review
- Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2023Review
- Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PD-L2 expression is an important predictor of anti-PD-1 therapy efficacy in patients with head and neck squamous cell carcinoma (HNSCC). However, whether the PD-L2-based immune signature can serve as a prognostic biomarker for patients with HNSCC remains unclear. Here, we reported that PD-L2 was positively stained in 62.7% of tumors, which was more than twice as that of PD-L1, and in 61.4% of patients with PD-L1-negative tumors. Survival tree analysis (STA) revealed that PD-L2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.